Injective (INJ) Trading Volume Soars 60% — Bullish Breakout Toward $16 Incoming?

Andrew Chen
Injective (INJ)

Getting your Trinity Audio player ready...

Key Takeaways:

  • INJ is up 19% weekly with a sharp 60% jump in volume, hinting at bullish investor behavior.
  • Analysts suggest a decisive breakout could come if INJ surpasses the $16 mark.
  • 2025 forecasts vary, but overall sentiment leans positive amid ETF and adoption growth.

Despite a 1.41% dip to $12.35 in the past 24 hours, Injective (INJ) continues to stand out with a solid weekly performance of 19.17%, signaling resilience in a largely consolidating crypto market. What’s more, trading volume has surged 60.13% to over $182 million, suggesting fresh investor interest in the token.

While most altcoins are cooling off, Injective’s bullish undertone is raising eyebrows among market watchers, particularly due to positive technical setups and increasing institutional attention.

Technical Analysts Eye $16 for INJ Breakout Confirmation

Renowned crypto analyst Lennaert Snyder believes Injective may have already bottomed out and is showing signs of entering a strong uptrend. He highlights that INJ has broken past key resistance zones and is now consolidating above strong support levels — a potential prelude to a major rally.

“The real breakout will happen when INJ goes past the $16 threshold,” Snyder explained. “Once that level is breached, expect rapid gains.”

The bullish sentiment is further reinforced by growing institutional demand, particularly around the Injective staked ETF, which is positioned to attract large capital inflows.

2025 Price Predictions Vary But Trend Is Positive

Looking ahead, price forecasts for Injective in 2025 show a broad range but remain cautiously optimistic.

While the outlooks differ, both see upside — hinging largely on how Injective performs in the coming months and whether the token can sustain current momentum and break above $16.

INJ Building Toward Breakout as Institutional Focus Grows

Despite short-term volatility, Injective is gaining traction on both retail and institutional fronts. Key levels, especially the $16 resistance, could dictate whether INJ sees exponential growth or remains range-bound.

Disclaimer: The information in this article is for general purposes only and does not constitute financial advice. The author’s views are personal and may not reflect the views of Chain Affairs. Before making any investment decisions, you should always conduct your own research. Chain Affairs is not responsible for any financial losses.

Related Posts